Biopharmaceutical therapeutics for asthma remodeling.
Current asthma therapy is aimed at controlling disease symptoms. A subset of asthma patients remains symptomatic despite optimal therapy indicating that an unmet medical need exists for these patients. Innovative therapeutics are needed to treat the unmet need in asthma and biopharmaceutical approaches may provide an opportunity for identifying these agents. It is proposed that airway remodeling contributes to asthma symptoms and this feature of disease pathology may be a target for future therapies. The current review focuses on the contribution of one feature of airway remodeling, subepithelial fibrosis, towards disease and highlights some of the mechanisms that may contribute to this feature of airway remodeling. Further, some potential molecular targets are identified for consideration for therapeutic intervention.
Das
A M
AM
Immunobiology, Centocor Inc., 145 King of Prussia Road, Radnor, PA, USA. adas2@cntus.jnj.com
Griswold
D E
DE
Torphy
T J
TJ
Li
L
L
D000818:Animals; D018927:Anti-Asthmatic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D001702:Biopharmaceutics; D006801:Humans; D020545:Respiratory Mucosa / Q000187:drug effects / Q000378:metabolism / Q000473:pathology
D018927:Anti-Asthmatic Agents